SU14. Characteristics Associated With Relapse in Patients With Schizophrenia: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Cariprazine Relapse Prevention Trial

ABSTRACT: Abstract Background: Relapse is common in schizophrenia; identifying characteristics associated with relapse may help improve disease management. Cariprazine, a D3/D2 receptor partial agonist, is approved in the United States for the treatment of schizophrenia. Post hoc analyses of a long-term, randomized, double-blind (up to 72 weeks), relapse prevention trial (NCT01412060) were performed to identify characteristics associated with relapse in placebo- and cariprazine-treated patients. Methods: Baseline characteristics in cariprazine-treated (3, 6, or 9 mg/d) or placebo-treated patients were evaluated in relation to relapse status. Demographic variables included age, sex, race, weight, and BMI. Psychiatric history variables included mean age at illness onset, duration of schizophrenia, dur

SUBMITTER: Kunovac J 

PROVIDER: S-EPMC5476044 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature